Nutrix develops CortiSense, a CES‑awarded device that measures cortisol in saliva and integrates with its gSense digital health platform (which includes continuous glucose monitoring, AI dietary management and telemedicine). The company pivoted its hardware roadmap toward CortiSense while maintaining an initial clinical focus on diabetes and other chronic diseases. CortiSense was developed with support from the University of Applied Sciences Northwestern Switzerland and the device launch has been used to kick off a U.S. rollout. Nutrix has operations launched in Mexico and Peru and its gSense platform is integrated with Chile’s public insurance system. The startup has received support from the Swiss innovation agency Innosuisse and private investors and plans to use funding to study cortisol’s links to women’s health, including perimenopause and menopause. With backing from Mayo Clinic, Nutrix is planning U.S. expansion and to open offices in Silicon Valley while preparing for a larger Series A.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2025